Latest Breaking News On - Lactic acidosis - Page 5 : comparemela.com

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases associated with cognitive impairment News provided by Share this article Share this article BOSTON, July 8, 2021 /PRNewswire/  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.  This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion s investigational therapeutics for neurological diseases associated with cognitive impairment.

United statesCarlo tanziJacob donoghueVerge scientific communicationsCyclerion therapeutics incSecurities exchangeAmerican academy of neurology glasserCyclerion therapeuticsBeacon biosignalsAmerican academyMitochondrial encephalomyopathyLactic acidosisCognitive impairment associatedChief scientific officerChief executive officerSecurities act